




PHARMACEUTICAL 2022

Virios Therapeutics Inc.
Rank 253 of 466





PHARMACEUTICAL 2022

Virios Therapeutics Inc.
Rank 253 of 466

The relative strengths and weaknesses of Virios Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Virios Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Virios Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 105%, being 27% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	15,777
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,276
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-319
Other Revenues	0
Property and Equipment	0
Research and Development	10,796
Selling, General and Administrative Expense	4,845

Output Variable	Value in 1000 USD
Assets	15,777
Liabilities	1,276
Expenses	15,641
Revenues	0
Stockholders Equity	14,501
Net Income	-15,960
Comprehensive Net Income	-15,960
Economic Capital Ratio	105%